PT - JOURNAL ARTICLE AU - Carreira, Helena AU - Strongman, Helen AU - Peppa, Maria AU - McDonald, Helen I AU - dos-Santos-Silva, Isabel AU - Stanway, Susannah AU - Smeeth, Liam AU - Bhaskaran, Krishnan TI - Prevalence of COVID-19-related risk factors and risk of severe influenza outcomes in cancer survivors: a matched cohort study using linked English electronic health records data AID - 10.1101/2020.10.08.20209304 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.08.20209304 4099 - http://medrxiv.org/content/early/2020/10/12/2020.10.08.20209304.short 4100 - http://medrxiv.org/content/early/2020/10/12/2020.10.08.20209304.full AB - Background People with active cancer are recognised as at risk of COVID-19 complications, but it is unclear whether the much larger population of cancer survivors is at elevated risk. We aimed to address this by comparing cancer survivors and cancer-free controls for (i) prevalence of comorbidities considered risk factors for COVID-19; and (ii) risk of severe influenza, as a marker of susceptibility to severe outcomes from epidemic respiratory viruses.Methods We included survivors (≥1 year) of the 20 most common cancers, and age, sex and general practice-matched cancer-free controls, derived from UK primary care data linked to cancer registrations, hospital admissions and death registrations. Comorbidity prevalences were calculated 1 and 5 years from cancer diagnosis. Risk of hospitalisation or death due to influenza was compared using Cox models adjusted for baseline demographics and comorbidities.Findings 108,215 cancer survivors and 523,541 cancer-free controls were included. Cancer survivors had more asthma, other respiratory, cardiac, diabetes, neurological, renal, and liver disease, and less obesity, compared with controls, but there was variation by cancer site. There were 205 influenza hospitalisations/deaths, with cancer survivors at higher risk than controls (adjusted HR 2.78, 95% CI 2.04-3.80). Haematological cancer survivors had large elevated risks persisting for >10 years (HR overall 15.17, 7.84-29.35; HR >10 years from cancer diagnosis 10.06, 2.47-40.93). Survivors of other cancers had evidence of raised risk up to 5 years from cancer diagnosis only (HR 2.22, 1.31-3.74).Interpretation Risks of severe COVID-19 outcomes are likely to be elevated in cancer survivors. This should be taken into account in policies targeted at clinical risk groups, and vaccination for both influenza, and, when available, COVID-19, should be encouraged in cancer survivors.Funding Wellcome Trust, Royal Society, NIHR.Evidence before this study Few data are available to date on how COVID-19 affects cancer survivors. We searched PubMed with the keywords “influenza cancer survivors” to identify studies that compared severe influenza outcomes in cancer survivors and in a control group. No study was identified.Added value of this study In this matched cohort study of routinely collected electronic health records, we demonstrated raised risks of influenza hospitalisation or mortality in survivors from haematological malignancies for >10 years after diagnosis, and in survivors from solid cancers up to 5 years after diagnosis.Implications of all the available evidence Cancer survivorship appears to be an important risk factor for severe influenza outcomes, suggesting that cancer survivors may also be at raised risk of poor COVID-19 outcomes. This should be taken into account in public health policies targeted at protecting clinical risk groups. Influenza vaccination should be encouraged in this group, and may need to be extended to a wider population of medium- to long-term cancer survivors than currently recommended.Competing Interest StatementDr. McDonald reports grants from NIHR Health Protection Research Unit in Immunisation, during the conduct of the study; Dr. Stanway reports personal fees from Roche, personal fees from Eli Lilly, personal fees from Novartis, outside submitted work; Dr. Bhaskaran reports grants from Wellcome Trust, grants from Royal Society, during the conduct of the study; all other authors have no conflicts of interest to disclose.Funding StatementThis work was supported by the National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Immunisation; and the Wellcome Trust and Royal Society (grant no. 107731/Z/15/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the London School of Hygiene & Tropical Medicine Ethics Committee (LSHTM Ethics Ref: 22416) and the Independent Scientific Advisory Committee for the Medicines and Healthcare products Regulatory Agency database research (20_082).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study is based in part on data from the Clinical Practice Research Datalink obtained under licence from the UK Medicines and Healthcare products Regulatory Agency. The terms of our licence to access the data preclude us from sharing individual patient data with third parties. The raw data may be requested directly from CPRD following their usual procedures.